Result of AGM

RNS Number : 3769D

Dechra Pharmaceuticals PLC

27 October 2020

 

Tuesday, 27 October 2020

Dechra^® Pharmaceuticals PLC

Results of Annual General Meeting (AGM)

A poll was held on each of the resolutions proposed at the Annual General Meeting (AGM) of the Company held today

 (27 October 2020).  All resolutions were passed and are as follows:

Resolution (No. as noted on proxy form)	Total For (includes Discretionary)		Total Against		Total Cast (excludes Withheld)		Withheld (1)
	No. of votes	% of vote	No. of votes	% of vote	No. of votes	% of vote	No. of votes
Ordinary Business:
Resolution 1: To receive the accounts, the Strategic Report, the Directors' Report and the Auditor's Report	80,530,666	99.77%	182,733	0.23%	80,713,399	74.67%	907,133
Resolution 2: To approve the Directors' Remuneration Report	81,088,589	99.36%	524,975	0.64%	81,613,564	75.51%	6,968
Resolution 3: To receive and approve the Directors' Remuneration Policy	74,112,644	90.81%	7,501,119	9.19%	81,613,763	75.51%	6,768
Resolution 4: To declare a final dividend	81,611,953	99.99%	8,079	0.01%	81,620,032	75.51%	500
Resolution 5: To elect Paul Sandland	80,408,925	98.52%	1,208,931	1.48%	81,617,856	75.51%	2,676
Resolution 6: To elect Alison Platt	80,875,757	99.09%	742,099	0.91%	81,617,856	75.51%	2,676
Resolution 7: To re-elect William Anthony Rice	71,921,431	88.82%	9,050,362	11.18%	80,971,793	74.91%	648,739
Resolution 8: To re-elect Ian Page	80,588,170	98.74%	1,028,236	1.26%	81,616,406	75.51%	4,126
Resolution 9: To re-elect Anthony Griffin	80,588,674	98.74%	1,027,732	1.26%	81,616,406	75.51%	4,126
Resolution 10: To re-elect Lisa Bright	72,640,656	89.00%	8,975,750	11.00%	81,616,406	75.51%	4,126
Resolution 11: To re-elect Julian Heslop	80,122,785	98.17%	1,492,511	1.83%	81,615,296	75.51%	5,236
Resolution 12: To re-elect Ishbel Macpherson	80,238,227	98.31%	1,379,629	1.69%	81,617,856	75.51%	2,676
Resolution 13: To re-elect Lawson Macartney	80,129,006	98.18%	1,487,380	1.82%	81,616,386	75.51%	4,146
Resolution 14: To re-appoint PricewaterhouseCoopers as external auditor of the company	81,607,914	99.99%	11,668	0.01%	81,619,582	75.51%	950
Resolution 15: To authorise the Audit Committee to determine the remuneration of the external auditor	81,616,178	100.00%	2,944	0.00%	81,619,122	75.51%	1,410
Special Business:
Resolution 16: To authorise the directors to allot shares to specific limits	76,917,382	94.24%	4,701,513	5.76%	81,618,895	75.51%	1,637
Resolution 17: To disapply the pre-emption rights	81,554,619	99.92%	63,753	0.08%	81,618,372	75.51%	2,160
Resolution 18: To disapply additional pre-emption rights	80,907,507	99.13%	710,766	0.87%	81,618,273	75.51%	2,259
Resolution 19: To authorise the Company to purchase its own shares	79,915,307	98.15%	1,509,708	1.85%	81,425,015	75.33%	195,517
Resolution 20: To authorise the Company to hold any general meeting (other than an AGM) on not less than 14 clear days' notice	80,053,146	98.08%	1,566,747	1.92%	81,619,893	75.51%	639

Notes:

1.  A "vote withheld" is not a vote in law and is not counted in the calculation of the proportion of votes "For" and "Against" a resolution.

2.  Resolutions 1 to 16 were ordinary resolutions, requiring more than 50% of shareholder votes to be "For" the resolutions.

3.  Resolutions 17 to 20 were special resolutions, requiring more than 75% of shareholder votes to be "For" the resolutions.

4.  Issued Share Capital at meeting date: 108,089,861.

5.  Equiniti, Registrar to the Company, were appointed for the purpose of the Poll taken at the AGM and certify as scrutineer that the result of the Poll is correctly set out above.

In accordance with Listing Rule 9.6.2R, a copy of the resolutions passed as special business at the AGM have been submitted to the National Storage Mechanism and will shortly be available for inspection at the FCA document viewing facility https://data.fca.org.uk/#/nsm/nationalstoragemechanism .

For further information, please contact:

Melanie Hall

Company Secretary

Dechra Pharmaceuticals PLC

Telephone: [phone]

Email: [e-mail]  

About Dechra

Dechra is a global specialist veterinary pharmaceuticals and related products business.  Our expertise is in the development, manufacture, marketing and sales of high quality products exclusively for veterinarians worldwide. The majority of Dechra's products are focused on key therapeutic categories where we have leading market positions, and many of our products are used to treat medical conditions for which there is no other effective solution or have a clinical or dosing advantage over competitor products.  For more information, please visit: www.dechra.com .

Trademarks

Trademarks appear throughout this document in italics.  Dechra and the Dechra "D" logo are registered trademarks of Dechra Pharmaceuticals PLC.

 

END

 

 

RAGEALEXAADEFFA